17 completed, 5 recruiting, 2 not yet recruiting, 2 terminated. 26 Phase 3, 1 Phase 2.
By phase and status
Follow Hereditary Autoinflammatory Diseases: new trials by email Literature Review of Hereditary Autoinflammatory Diseases trials Research Report on Hereditary Autoinflammatory Diseases
Trials (filtered) newest first · largest first
All 26 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever RPH-104 - Familial Mediterranean Fever, FMF | Phase 3 | Not yet recruiting | 18 | 2026-12-01 | 2026-10-19 |
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome Corticosteroids + Rivaroxaban, Corticosteroids alone - Behcet Syndrome | Phase 3 | Recruiting | 134 | 2025-06-24 | 2026-04-23 |
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease Placebo plus immunosuppression, Rivaroxaban plus immunosupression - Behcet Disease, Behcet Disease and Vascular Involvement | Phase 3 | Not yet recruiting | 110 | 2025-04-30 | 2025-04-13 |
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy ANAKINRA - FMF | Phase 3 | Recruiting | 50 | 2024-06-04 | 2025-06-25 |
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease Hemay005, Placebo - Behçet's Disease | Phase 3 | Recruiting | 162 | 2023-11-13 | 2025-04-08 |
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis Apremilast - Behçet's Disease, Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | 48 | 2023-03-23 | 2026-11-04 |
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease Apremilast, Placebo - Behçet Disease | Phase 3 | Recruiting | 60 | 2021-09-09 | 2026-07-24 |
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Infliximab, Cyclophosphamide - Behcet's Disease, Vasculitis | Phase 3 | Completed | 53 | 2018-05-25 | 2023-07-03 |
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | 28 | 2017-06-30 | 2021-02-23 |
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Infliximab - Behcet Disease | Phase 3 | Completed | 33 | 2015-07-22 | 2019-10-17 |
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease Apremilast, Placebo - Behçet's Syndrome | Phase 3 | Completed | 207 | 2014-12-30 | 2021-07-22 |
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | Phase 3 | Completed | 31 | 2014-11-03 | 2020-05-19 |
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Placebo, Gevokizumab - Behcet's Disease Uveitis | Phase 3 | Terminated | 4 | 2014-11-01 | 2015-12-29 |
Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Kineret - Familial Mediterranean Fever | Phase 3 | Completed | 25 | 2012-11-01 | 2024-04-02 |
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome | Phase 3 | Completed | 17 | 2012-01-16 | 2018-09-11 |
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions TA-650 - Behcet's Disease, Behcet Syndrome | Phase 3 | Completed | 18 | 2012-01-01 | 2026-01-07 |
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease ACZ885 - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome | Phase 3 | Completed | 17 | 2010-11-01 | 2017-03-29 |
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada canakinumab (company code: ACZ885D) - Cryopyrin Associated Periodic Syndrome | Phase 3 | Completed | 4 | 2010-08-01 | 2017-03-21 |
Phase III Study in Refractory Behcet's Disease AIN457, Placebo - Behcet Disease | Phase 3 | Completed | 118 | 2009-10-01 | 2015-08-31 |
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase canakinumab - Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome | Phase 3 | Completed | 19 | 2009-10-01 | 2020-09-25 |
Showing 20 of 26. Sign in to see all of them.
Narrower conditions
Behcet Syndrome (13) · Cryopyrin-Associated Periodic Syndromes (9) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Familial Mediterranean Fever (4) · Uveitis (3) · Arthritis, Juvenile (2) · Oral Ulcer (2) · Panuveitis (2) · Uveitis, Posterior (2) · Amyloidosis (1) · Arthralgia (1) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans Syndrome (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1)
Broader conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Genetic Diseases, Inborn (25) · Skin and Connective Tissue Diseases (23) · Skin Diseases (22) · Skin Diseases, Genetic (22) · Skin Diseases, Vascular (22) · Cardiovascular Diseases (13) · Eye Diseases (13) · Mouth Diseases (13) · Stomatognathic Diseases (13) · Uveal Diseases (13) · Uveitis, Anterior (13) · Vascular Diseases (13) · Vasculitis (12)
Interventions
canakinumab (8) · apremilast (3) · Cyclosporine (2) · Infliximab (2) · Interferon alpha-2 (2) · Interleukin 1 Receptor Antagonist Protein (2) · Rivaroxaban (2) · Adrenal Cortex Hormones (1) · Cyclic Nucleotide Phosphodiesterases, Type 4 (1) · Cyclophosphamide (1) · Hemay005 (1) · Immune Tolerance (1) · Immunosuppression Therapy (1) · Pharmaceutical Preparations (1) · gevokizumab (1)
Sponsors
Novartis Pharmaceuticals (7) · Amgen (3) · Assistance Publique - Hôpitaux de Paris (3) · Novartis (2) · Bellus Health Inc. - a GSK company (1) · Ganzhou Hemay Pharmaceutical Co., Ltd (1) · Janssen Korea, Ltd., Korea (1) · Marmara University (1) · Peking Union Medical College Hospital (1) · R-Pharm (1) · Regeneron Pharmaceuticals (1) · Sheba Medical Center (1) · Tanabe Pharma Corporation (1) · University Hospital Tuebingen (1) · XOMA (US) LLC (1)
Countries
France (12) · Spain (8) · United States (8) · Germany (7) · Turkey (Türkiye) (7) · Israel (6) · United Kingdom (6) · Italy (5) · Greece (4) · Switzerland (4) · Belgium (3) · Canada (3) · India (3) · Japan (3) · South Korea (3)
Top investigators
Avi Livneh, professor (1) · Fatma Alibaz-Oner, Prof (1) · Ina Koetter, MD (1) · Kazuoki Kondo, MD (1) · Mikhail Samsonov (1) · Robert Evans, PharmD. (1) · Shunsei Hirohata, MD (1) · Toshifumi Hibi, MD (1) · Yoshiaki Ishigatsubo, MD, Ph.D (1) · Zhanguo Li, Doctor (1)
Results publications
PMID 31161734, PMID 17554116, PMID 18668535, PMID 19494217, PMID 21859692, PMID 22152723, PMID 23031624, PMID 23290985, PMID 23380020, PMID 24906637, PMID 27310969, PMID 27860460, PMID 31722152, PMID 35798511, PMID 36578194, PMID 37316690
NIH funding
2009 (2), 2014 (2), 2023 (2)